Skip to main content
SpringerLink
Log in

Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson’s disease

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Abstract

We present a review of the literature on dopamine receptor agonists along with our own data on the treatment of Parkinson’s disease (PD) with Mirapex, which was used in 30 patients (mean age 61.8 ± 7.7 years, duration of disease 8.4 ± 1.3 years). Mirapex was used at a dose of 3.5 ± 1.1 mg/day on the background of treatment with levodopa preparations. The efficacy of Mirapex was assessed using quantitative scales. Improvements were demonstrated in general state, motor activity, daily activities, and the quality of life. Attention is drawn to a decrease in the severity of motor fluctuations and dyskinesias and in anxiety and depression, and to improvements in cognitive functions. The significance of the combination of the high efficacy and good tolerance of this agent is emphasized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. V. L. Golubev, Ya. I. Levin, and A. M. Vein, Parkinson’s Disease and Parkinsonism Syndrome [in Russian], MEDpress, Moscow (1999).

    Google Scholar 

  2. M. R. Nodel’, D. V. Artem’ev, and N. N. Yakhno, “The efficacy of the dopamine agonist Mirapex in Parkinson’s disease,” Nevrol. Zh., 4, 45–49 (1999).

    Google Scholar 

  3. N. V. Fedorova and V. N. Shtok, “Strategy and tactics in the treatment of Parkinson’s disease,” Konsilium, 3, No. 5, 237–242 (2001).

    Google Scholar 

  4. V. N. Shtok and N. V. Fedorova, The Treatment of Parkinsonism [in Russian], Moscow (1997).

  5. V. N. Shtok and N. V. Fedorova, “Current concepts in the treatment of parkinsonism,” Rus. Med. Zh., 6, No. 13, 837–844 (1998).

    Google Scholar 

  6. N. N. Yakhno, “Current approaches to the treatment of Parkinson’s disease,” Klin. Farmakol. Ter. No. 3–4, 92–97 (1994).

  7. P. Carvey, S. Pieri, and Z. Ling, “Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole,” J. Neural Transm., 104, 209–228 (1997).

    Article  PubMed  CAS  Google Scholar 

  8. J. M. Cedarbaum, “Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson’s disease,” Neurol. Clin., 8, 31–49 (1990).

    PubMed  CAS  Google Scholar 

  9. T. N. Chase and J. F. Oh, “Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications,” Ann. Neurol., 47,Supplement 1, 122–129 (2000).

    Google Scholar 

  10. G. Cohen, “Oxygen radicals and Parkinson’s disease,” in: Oxygen Radicals and Tissue Injury. B. Halliwell (ed.) (1988), pp. 130–135.

  11. M. C. Caldwell, I. Boyfield, T. Brown, et al., “Comparison of the functional potencies of ropinerole and other dopamine receptor agonists at human D2 (long), D3 and D4 receptors expressed in Chinese hamster ovary cells,” Brit. J. Pharmacol., 127, No. 7, 1696–1702 (1999).

    Article  Google Scholar 

  12. M. H. Corrigan, A. Q. Denahan, C. E. Wright, and R. J. Ragual, “Comparison of pramipexole, fluoxetine, and placebo in patients with major depression,” Depress. Anxiety, 11, 58–65 (2000).

    Article  PubMed  CAS  Google Scholar 

  13. S. Fahn, “Adverse effects of levodopa,” in: The Scientific Basis for the Treatment of Parkinson’s Disease, C. W. Olanow and A. N. Lieberman (eds.), Carnforth, UK (1992), pp. 89–112.

  14. S. T. Gancher, “Pharmacology of Parkinson’s disease,” in: Parkinson’s Disease, S. J. Huber and J. L. Cummings (eds.), New York (1992), pp. 273–287.

  15. C. G. Goetz, “Dopaminergic agonists in the treatment of Parkinson’s disease,” Neurology, 40,Supplement 3, 50–54 (1990).

    PubMed  Google Scholar 

  16. M. Guttman, “Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease,” Neurology, 49,Supplement 4, 1060–1065 (1997).

    PubMed  CAS  Google Scholar 

  17. R. G. Holloway, “The Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson’s disease: a four-year randomized controlled trial,” Neurology, 58, 81–82 (2000).

    Google Scholar 

  18. J. P. Hubble, W. C. Koller, N. R. Cutler, et al., “Pramipexole in patients with early Parkinson’s disease,” Clin. Neuropharmacol., 18, No. 4, 338–347 (1995).

    Article  PubMed  CAS  Google Scholar 

  19. M. Kreider and S. Knox, “A multicenter double-blind study of ropinirole as an adjunct to l-dopa in Parkinson’s disease [abstract],” Neurology, 46,Supplement, 475 (1996).

    Google Scholar 

  20. A. E. Lang, “Are the new dopamine agonists better than the old ones?” in: Sixth International Congress of Parkinson’s Disease and Movement Disorders, Barcelona (2000).

  21. A. Lieberman, S. Imke, M. Muenter, et al., “Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson’s disease patients with fluctuating responses to levodopa/carbidopa,” Neurology, 43, 1981–1984 (1993).

    PubMed  CAS  Google Scholar 

  22. A. Lieberman, A. Ranhosky, and D. Korts, “Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study,” Neurology, 49, No. 1, 162–168 (1997).

    PubMed  CAS  Google Scholar 

  23. G. Linazasoro, “On behalf of Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to pramipexole,” J. Neurol., 251, 335–339 (2004).

    Article  PubMed  CAS  Google Scholar 

  24. C. D. Marsden, “The mysteries of motor function of the basal ganglia: the Robert Wartenburg lecture,” Neurology, 32, 514–539 (1982).

    PubMed  CAS  Google Scholar 

  25. C. D. Marsden, “Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 57, 672–681 (1994).

    PubMed  CAS  Google Scholar 

  26. E. S. Molho, S. A. Factor, W. J. Weiner, et al., “The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson’s disease,” J. Neural. Transm., 45,Supplement, 225–230 (1995).

    CAS  Google Scholar 

  27. D. Nyholm, H. Lennernas, C. Trolin, et al., “Plasma levodopa concentrations in parkinsonian patients during activities of daily living,” in: The Movement Disorder Society’s 6th International Congress of Parkinson’s Disease and Movement Disorders, Barcelona (2000).

  28. N. Ogawa, I. Miyazaki, K. Tanaka, et al., “Dopamine D2 receptor mediated antioxidant and neuroprotective effects of ropinirole,” in: XIII International Congress on Parkinson’s Disease, Vancouver (1999).

  29. C. W. Olanow, “Oxidation reactions in Parkinson’s disease,” Neurology, 40Supplement 3, 32–37 (1990).

    PubMed  Google Scholar 

  30. C. W. Olanow, “A rationale for dopamine agonists as primary therapy for Parkinson’s disease,” Can. J. Neurol. Sci., 19, 108–112 (1992).

    PubMed  CAS  Google Scholar 

  31. J. D. Parkes, N. Schachter, C. D. Marsden, et al., “Lisuride in parkinsonism,” Ann. Neurol., 9, 48–52 (1981).

    Article  PubMed  CAS  Google Scholar 

  32. “Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism,” Neurology, 55, 1540 (2000).

    Google Scholar 

  33. “Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD study,” J. Clin. Neuropharmacol., 23, No. 1, 34–44 (2000).

    Google Scholar 

  34. H. L. Paulson and M. B. Stern, Movement Disorders: Neurologic Principles and Practice, New York (1997), pp. 183–199.

  35. M. F. Piercey, W. E. Hoffmann, M. W. Smith, et al., “Inhibition of dopamine neuron firing by pramipexole, a dopamine D, receptor-preferring agonist: comparison to other dopamine receptor agonists,” Eur. J. Pharmacol., 312, No. 1, 35–44 (1996).

    Article  PubMed  CAS  Google Scholar 

  36. M. M. Pinter, O. Pogarell, and W. H. Ortel, “Efficacy, safety and tolerance of non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double-blind, placebo controlled, randomized, multicentre study,” J. Neurol. Neurosurg. Psychiat., 66, No. 4, 436–441 (1999).

    Article  PubMed  CAS  Google Scholar 

  37. W. H. Poewe and G. K. Kenning, “The natural history of Parkinson’s disease,” Ann. Neurol., 44,Supplement 1, 1–9 (1998).

    Google Scholar 

  38. O. Pogarell, T. Gasser, J. J. van Hilten, et al., “Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomized double-blind, placebo controlled, multicentre study,” J. Neurol. Neurosurg. Psychiat., 72, No. 6, 713–720 (2002).

    Article  PubMed  CAS  Google Scholar 

  39. R. M. Post, R. H. Gerner, J. S. Carman, et al., “Effects of dopamine agonist piribedil in depressed patients: relationship of pre-treatment homovanillic acid to antidepressant response,” Arch. Gen. Psychiat., 35, No. 5, 609–615 (1978).

    PubMed  CAS  Google Scholar 

  40. N. Quinn, “Drug treatment of Parkinson’s disease,” Brit. Med. J., 310,Supplement 6979, 575–579 (1995).

    PubMed  CAS  Google Scholar 

  41. A. H. Rajput, “Adverse effects of ergot-derivative dopamine agonists,” in: Dopamine Agonists in Early Parkinson’s Disease, C. W. Olanow and J. E. Obeso (eds.), Kent, UK (1997), pp. 209–216.

  42. O. A. Rascol, “A double blind l-dopa controlled study of ropinirole patients with early Parkinson’s disease,” Neurology, 46,Supplement, 139 (1996).

    Google Scholar 

  43. H. Reichmann, H. M. Brecht, P. J. Kraus, et al., “Pramipexole in Parkinson’s disease. Results of a treatment observation,” Nervenarzt, 73, No. 8, 745–750 (2002).

    Article  PubMed  CAS  Google Scholar 

  44. U. K. Rinne, “Early dopamine agonist treatment in Parkinson’s disease,” in: Parkinson’s Disease: the Role of Dopamine Agonists, A. Lieberman and X. Lataste (eds.), Lanes (1989), pp. 29–33.

  45. U. K. Rinne, “A five year double blind study with cabergoline versus levodopa in the treatment of early Parkinson’s disease,” in: XIII International Congress on Parkinson’s Disease, Vancouver (1999).

  46. F. Sautel, N. Griffon, D. Levesque, et al., “A functional test identifies dopamine agonists selective for D3 versus D2 receptors,” NeuroReport, 6, No. 2, 329–332 (1995).

    Article  PubMed  CAS  Google Scholar 

  47. M. Schroder, A. Kühn, and A. Kupsch, “Impaired tonic vigilance associated with pramipexole,” in: Sixth International Congress of Parkinson’s Disease and Movement Disorders, Barcelona (2000).

  48. K. M. Shannon, J. P. Bennett, and J. H. Friedman, “Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group,” Neurology, 49, No. 724–728 (1997).

    Google Scholar 

  49. R. P. Snaith, M. Hamilton, S. Morley, et al., “A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale,” Brit. J. Psychiat., 167, No. 1, 99–103 (1995).

    PubMed  CAS  Google Scholar 

  50. W. G. Tatton, W. Y. H. Ju, J. Wadia, et al., “Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy,” in: Neurodegeneration and Neuroprotection in Parkinson’s Disease, C. W. Olanow, P. Jenner, and M. H. B. Youim (eds.), London (1996), pp. 202–220.

  51. “The Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson’s disease. A randomized dose-ranging study,” J. Am. Med. Assoc., 278, No. 2, 125–130 (1997).

    Google Scholar 

  52. “The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a randomized controlled trial,” J. Am. Med. Assoc., 284, No. 15, 1931–1938 (2000).

    Google Scholar 

  53. J. Waehrens and J. Gerlach, “Bromocriptine and imipramine in endogenous depression: a double-blind controlled trial in out-patients,” J. Affect. Disord., 3, No. 2, 193–202 (1981).

    Article  PubMed  CAS  Google Scholar 

  54. W. J. Wiener and A. E. Lang, Movement Disorders: a Comprehensive Survey, Mount. Kisco, New York (1989).

  55. L. Wermuth, “A double-blind, placebo-controlled, randomized, multicenter study of pramipexole in advanced Parkinson’s disease,” Eur. J. Neurol., 5, No. 3, 235–242 (1998).

    Article  PubMed  Google Scholar 

  56. E. C. Wolters, G. Tissingh, P. L. M. Bergmans, et al., “Dopamine agonists in Parkinson’s disease,” Neurology, 45,Supplement 3, 28–34 (1995).

    Google Scholar 

  57. G. F. Wooten, “Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson’s disease,” Ann. Neurol., 24, 363–365 (1988).

    Article  PubMed  CAS  Google Scholar 

  58. A. Zenzola, C. Diroma, A. Fraddosio, et al., Efficacy and Tolerability of Dopamine Agonists in a Parkinsonian Population, Bar (2000).

  59. M. Ziegler and P. Rondor, “Activity of piribedil in Parkinson’s disease: a multicenter study,” Presse Med., 28, 1414–1418 (1999).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Russian Medical Postgraduate Academy, Federal Agency for Health and Social Development (Roszdrav), Russia

    N. V. Fedorova & I. P. Chigir’

  2. Center for Extrapyramidal Diseases, Ministry of Health and Social Development, Moscow

    N. V. Fedorova & I. P. Chigir’

Authors
  1. N. V. Fedorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. P. Chigir’
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

__________

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 106, No. 6, pp. 26–33, June, 2006.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fedorova, N.V., Chigir’, I.P. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson’s disease. Neurosci Behav Physiol 37, 539–546 (2007). https://doi.org/10.1007/s11055-007-0050-3

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-007-0050-3

Key words

Search

Navigation